Peri-operative management of anti-platelet agents and anti-thrombotic agents in geriatric patients undergoing semi-urgent hip fracture surgery by Lau, TW et al.
Title
Peri-operative management of anti-platelet agents and anti-
thrombotic agents in geriatric patients undergoing semi-urgent
hip fracture surgery
Author(s) Ho, HH; Lau, TW; Leung, F; Tse, HF; Siu, CW
Citation Osteoporosis International, 2010, v. 21 SUPPL. 4, p. S573-S577
Issued Date 2010
URL http://hdl.handle.net/10722/135288
Rights The Author(s)
REVIEW
Peri-operative management of anti-platelet agents
and anti-thrombotic agents in geriatric patients undergoing
semi-urgent hip fracture surgery
H. H. Ho & T. W. Lau & F. Leung & H-F. Tse & C-W. Siu
Received: 18 August 2010 /Accepted: 14 September 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Hip fractures are common events in the geriatric
population and are often associated with significant morbidity
and mortality. Over the coming decades, the size of the
greying population is forecast to increase and hence, the
annual incidence of hip fracture is expected to rise substan-
tially. Several studies have shown that hip fracture surgery
performed within 24 to 48 h of hospitalisation significantly
reduces mortality. Medical specialists including cardiologists
are often involved in the care of these geriatric patients as
most of them have comorbid conditions that must be managed
concomitantly with their fracture. Cardiovascular and throm-
boembolic complications are among some of the commonest
adverse events that could be experienced by these elderly
patients during hospitalisation. We review in this article the
current recommendations and controversies on the peri-
operative management of anti-platelet agents and anti-
thrombotic agents in geriatric patients undergoing semi-
urgent hip fracture surgery.
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Introduction
Hip fractures are common events in the geriatric population
and are often associated with significant morbidity and
mortality. Mortality from hip fracture [1] approaches 20% or
more at 1 year. Of those who survive to 6 months [2], only
60% recover their prefracture walking ability. Approximately
25% of the individuals [3] who were living independently
before the fracture require long-term nursing care.
Hip fracture is considered a surgical disease; thus,
prompt surgical correction is necessary for preservation of
function. The surgery [4] itself carries a 4% mortality risk.
Medical specialists [5] including cardiologists are often
involved in the care of these geriatric patients as most of
them have comorbid conditions that must be managed
concomitantly with their fracture. Cardiovascular and
thromboembolic complications are among some of the
commonest adverse events that could be experienced by
these elderly patients during hospitalisation besides infec-
tion, delirium, etc., which could potentially contribute to
the risk of functional decline, nursing home admission and
mortality.
This review article will focus on three parts:
1. periprocedural management of patients with hip frac-
ture, who happened to be taking anti-platelet agents
(single or dual) for underlying coronary artery disease
with particular emphasis on those who received
coronary stents,
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2. general overview of the thromboembolic prophylaxis in
geriatric patients undergoing semi-urgent hip fracture
surgery,
3. discussion on regional anaesthesia.
Timing of surgical intervention for hip fracture
Hip fracture surgery should be performed within 24 to 48 h
of hospitalisation for patients who are medically stable and
without significant comorbidities. Most studies [6–10] have
shown that surgical repair within this timeframe signifi-
cantly reduces mortality.
For patients with active comorbid medical conditions,
such as unstable angina, congestive heart failure, chronic
obstructive pulmonary disease, etc., it is prudent to delay
the operation to as long as 72 h and optimise their medical
conditions first.
Anti-platelet agents
The two most common anti-platelet agents encountered in
clinical practice are aspirin and thienopyridines (e.g.,
clopidogrel and ticlopidine). They are usually taken by
patients with atherothrombotic disease. Some patients may
be taking dual anti-platelet therapy due to implantation of
coronary artery stents, acute coronary syndrome and
cerebrovascular disease. Anti-platelet agents are often
stopped before elective surgery in order to reduce
procedure-related bleeding. The decision to discontinue
anti-platelet agents before hip fracture surgery should take
into account the potential risk of stopping the medications,
and consultation with the patient's cardiologist or neurolo-
gist should be considered prior to any decision.
Aspirin
A meta-analysis [11] of ten orthopaedic trauma trials found
that aspirin significantly reduced the rate of deep venous
thrombosis and pulmonary embolism compared with
placebo. However, this reduction was significantly less
when compared with other agents like warfarin and low-
molecular-weight heparin. Hence, aspirin alone provides
some although suboptimal protection against thromboem-
bolic events after hip fracture.
For patients with coronary artery stents, non-cardiac
surgery increases the risk of stent thrombosis, myocar-
dial infarction and death especially if the patients
undergo hip fracture surgery early after stent implanta-
tion. Peri-operative or post-operative stent thrombosis is
a life-threatening complication for patients with either
bare-metal or drug-eluting stents. It is generally recom-
mended that for such patients, aspirin must be continued
throughout the peri-operative period [12] as it does not
appear to increase the risk of significant bleeding after hip
fracture surgery.
Thienopyridines
Thienopyridines (e.g., clopidogrel and ticlopidine) are often
used in combination with aspirin. Dual anti-platelet therapy
is especially important in patients who have undergone
coronary stent implantation. For patients with history of
coronary stenting who present with hip fracture, it is
important to know the date of the last percutaneous
coronary intervention and the type of stent put in.
There are limited data regarding the management of
patients on dual anti-platelet agents with a recently placed
coronary stent who require a semi-urgent hip fracture
surgery. Discontinuation of anti-platelet therapy in these
patients confers significant morbidity and mortality [13–16]
because stent endothelialisation may not be complete at the
time of surgery and combined with prothrombotic state
induced by surgery increases the risk of acute peri-operative
stent thrombosis and myocardial infarction.
There is also little evidence [12, 17] to define the true
impact of continuing thienopyridine on bleeding in non-
cardiac surgery. When compared with aspirin alone, the
combination of clopidogrel and aspirin increases the
absolute risk of major bleeding by 0.4–1.0%.
The American College of Cardiology and American
Heart Association guidelines [18] recommend that when-
ever possible, elective or semi-elective procedures should
be postponed until the patient has received at least the
minimum length of dual anti-platelet therapy depending on
whether bare-metal(BMS) or drug-eluting stent(DES) was
implanted.
At present, there is no definitive standard of care [19–21]
on the optimum peri-operative anti-platelet regimen in
patients with coronary stents particularly those with drug-
eluting stents. As mentioned earlier, aspirin can be
continued peri-operatively regardless of whether patient
had received BMS or DES. For patients who had BMS
implantation at least 4 weeks ago prior to admission or DES
implantation at least 12 months ago, the thienopyridine can
be stopped if surgical bleeding is a concern.
The clinical delimma comes when we are faced with
patients who present with hip fracture and had undergone
BMS implantation <4weeks orDES implantation <12months
ago. There are three options that can be considered for the
anti-platelet regimen. Firstly, one can choose to continue dual
anti-platelet therapy [22] throughout the peri-operative period
if possible. Secondly, since anti-thrombotic agents (e.g., low-
molecular-weight heparin) are often used as thromboembolic
prophylaxis in hip fracture, one can implement it as bridging
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therapy [21] to substitute for dual anti-platelet therapy.
Although success with bridging therapy has been reported,
prospective studies are necessary to validate it as a viable
management strategy. Recent studies [23] have recommen-
ded bridging therapy with glycoprotein IIb/IIIa inhibitors
primarily for those who have not completed dual anti-platelet
therapy and in patients whose stent complexities and
comorbidities significantly increase their risk for developing
catastrophic stent thrombosis. The final option is discontinue
thienopyridine preoperatively and following the hip fracture
surgery, the thienopyridine should be restarted [24], with or
without a loading dose, as soon as it is deemed safe.
Primary percutaneous coronary intervention is the
definitive treatment for peri-operative stent thrombosis as
administration of thrombolytic is contraindicated in patients
with recent surgery. Hence, for patients with previous
coronary stenting, hip fracture surgery should ideally be
performed in institutions where 24 h interventional cardiology
services are available to provide emergent intervention if the
need arises.
Anti-thrombotic agents for thromboembolic prophylaxis
Venous thromboembolism is one of the leading causes of
peri-operative morbidity and mortality in patients with hip
fracture. In the absence of thromboembolic prophylaxis, the
prevalence of venography-detected proximal deep venous
thrombosis was 27% in patients who had undergone hip
fracture surgery [25]. The incidence of fatal pulmonary
embolism ranges from 0.4% to 7.5% of patients within
3 months of hip fracture surgery.
Although thromboembolic prophylaxis is a routine
aspect of care in patients with hip fracture, there is no
clear-cut guideline regarding the optimal agent, the timing
and duration of prophylaxis. Whether to initiate thrombo-
embolic prophylaxis before or immediately after surgery is
still unclear.
Deep venous thrombosis may begin as early as the time
of hip fracture. Until more definitive data is available, it is
reasonable to initiate anti-thrombotic therapy as soon as
patient is admitted into hospital. The American College of
Chest Physicians (ACCP)guidelines [26] recommend the
use of three agents for thromboembolic prophylaxis namely
fondaparinux, unfractionated heparin (UFH) and low-
molecular-weight heparin (LMWH).
Fondaparinux
Fondaparinux is a synthetic highly sulfated pentasaccharide
that binds to anti-thrombin with a higher affinity than
heparin and is recommended as an option for first-line
prophylactic therapy.
In the largest randomised trial [27] of thromboprophy-
lactic therapy to prevent venous thromboembolism in
patients with hip fracture, the incidence of venous throm-
boembolism(8.3% versus 19.1%) was significantly lower in
the group of patients receiving subcutaneous fondaparinux
2.5 mg once daily when compared to those receiving
subcutaneous enoxaparin 40 mg daily. Despite superior
efficacy, its main drawback is the high cost which hampers
its wide clinical application.
Unfractionated heparin
Low-dose UFH (5,000 U subcutaneous administration
twice daily) has been the agent [28] most frequently studied
for thromboembolic prophylaxis. Several studies have
shown that UFH heparin significantly reduced the risk of
deep venous thrombosis when compared to placebo in
patients undergoing hip fracture surgery with a slight
increase risk of post-operative bleeding.
Low-molecular-weight heparin
LMWH confers similar reduction in the risk of thrombo-
embolic disease when compared to low-dose UFH. A
systematic review [29] of 31 trials involving 3,000 patients
with hip fracture could not determine the superiority of
either form of heparin.
Recommended regimens for enoxaparin are 30 mg
subcutaneously every 12 h or 40 mg once daily. LMWH
are cleared principally by the renal route and their half-life
is prolonged in patients with renal failure. The dosage of
enoxaparin must be adjusted for elderly patients who often
have renal impairment. Studies of LMWH have reported
that the incidence of post-operative bleeding is similar to
bleeding rates observed with UFH.
However, the incidence of heparin-induced thrombocy-
topenia is lower with LMWH than UFH.
Duration of thromboembolic prophylaxis
At present, it seems reasonable to continue prophylaxis
until the patient is fully ambulatory. Prophylaxis may be
extended [26] for a longer duration for high-risk patients,
e.g., those who developed prolonged immobility, previous
history of venous thromboembolism, etc.
New agents
Oral direct thrombin inhibitors are emerging as new agents for
anti-thrombotic therapy in patients with risk of thromboem-
bolism. Dabigatran [30] is currently being investigated for
prophylaxis of deep venous thrombosis and thromboembolic
disease in patients undergoing hip replacement surgery.
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Regional anaesthesia
Patients with hip fracture can be put under general or
regional anaesthesia for the corrective surgery. Certain
precautions pertaining to regional anaesthesia need to be
taken into account with regards to anti-platelet and anti-
thrombotic agents.
In patients with coronary artery stents, the use of
regional anaesthesia must be carefully considered. Studies
[31, 32] have shown that regional anaesthesia attenuates the
hypercoagulable peri-operative state and also provides anti-
platelet effects by decreasing platelet aggregation. Stent
thrombosis may occur in higher-risk patients if anti-platelet
agents are discontinued.
The American Society of Regional Anaesthesia
(ASRA) 2003 guidelines [33] consider the use of
thienopyridines and dual anti-platelet agents as relative
contraindications to neuraxial anaesthesia or peripheral
nerve blockade in non-compressible regions that cannot be
observed for bleeding. The actual risk of spinal hematoma
is unknown in this subgroup of patients, and there have
been case reports of this adverse complication in the
presence of anti-platelet and anti-thrombotic agents.
Although the ASRA recommends discontinuing clopidog-
rel 7 days and ticlopidine 14 days before regional
anaesthesia, variances from their recommendation may
be acceptable based on the clinical judgement of the
responsible anaesthesiologist.
Aspirin alone does not appear to increase the risk of spinal
hematoma. However, concurrent use [34, 35] of UFH or
LMWH increases the risk of bleeding and spinal hematoma
in the presence of aspirin monotherapy. In patients receiving
LMWH alone, the current ASRA guidelines recommend
delaying neuraxial blockade at least 10–12 h after the last
LMWH dose. LMWH has also been reported to cause
bleeding/hematoma within the spinal column in patients
receiving regional anaesthesia. The United States Food and
Drug Administration (FDA) [36] recommend that patients
receiving regional anaesthesia who are treated with LMWH
should be monitored frequently for signs and symptoms of
neurologic impairment. Current ASRA guidelines [33]
recommend removal of epidural catheter 1 h before
administration of UFH and 2 h before LMWH. The
appropriate time interval between catheter removal and
clopidogrel administration remains undefined.
Summary and recommendations
Patients with hip fracture who are medically stable and free
of significant comorbidities should undergo surgical cor-
rection within 24 to 48 h in order to obtain the best chance
for functional recovery and survival.
For those taking anti-platelet agents, aspirin should be
continued throughout the peri-operative period as its benefit
outweighs the risk of bleeding. As for patients with history
of coronary stenting and taking thienopyridine on top of
aspirin, clinical judgement is of utmost importance in
balancing the risk/benefit ratio of dual anti-platelet therapy
interruption versus continuation. Good communication
between the patient's cardiologist, surgeon and anaesthesi-
ologist is essential to achieve a favourable outcome for the
patient and to minimise the risk of catastrophic stent
thrombosis.
As patients with hip fracture are also prone to venous
thromboembolism, thromboembolic prophylaxis should be
instituted as early as possible in patients awaiting surgery.
Precautions are necessary for patients taking dual anti-
platelet agents and receiving thromboembolic prophylaxis
when considering regional anaesthesia for surgery. The
decision to perform regional anaesthesia should be made on
individual basis with full consideration given to all
potential complications.
Future studies are necessary to determine the optimal
peri-operative treatment strategies for patients on anti-
platelet agents and on thromboembolic prophylaxis when
they undergo hip fracture surgery.
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